Compounded vs Brand-Name GLP-1s: What Telehealth Patients Need to Know (2026)

If you have been shopping for a GLP-1 telehealth program, you have almost certainly encountered two very different pricing tiers. Brand-name Wegovy might cost $1,350 per month without insurance. Compounded semaglutide from a telehealth platform might cost $200 to $400. The same active ingredient, but a dramatically different price — and a set of important differences that every patient should understand before choosing.

This guide explains what compounded GLP-1 medications are, how they differ from brand-name versions, what the regulatory picture looks like, and how to evaluate whether a telehealth provider's compounding approach meets a reasonable standard of safety.

What Are Brand-Name GLP-1 Medications?

The term "brand-name" refers to products that have gone through the full FDA approval process. For GLP-1 medications used in weight management, the key products are:

• Wegovy (semaglutide 2.4mg, weekly injection) — FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition
• Ozempic (semaglutide up to 2mg, weekly injection) — FDA-approved for type 2 diabetes; prescribed off-label for weight loss by many providers
• Zepbound (tirzepatide, weekly injection) — FDA-approved for chronic weight management
• Mounjaro (tirzepatide, weekly injection) — FDA-approved for type 2 diabetes; prescribed off-label for weight loss

Brand-name products are manufactured by pharmaceutical companies (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide) under strict FDA oversight. They have defined doses, standardized formulations, proven bioavailability data from clinical trials, and supply chains subject to federal inspection.

The primary disadvantage is cost. Without insurance, brand-name GLP-1s for weight management typically run $800 to $1,400 per month.

What Is Compounded Semaglutide?

Compounded medications are prepared by licensed compounding pharmacies that combine, mix, or alter ingredients to create a customized drug product. Compounding is legal and serves an important function — for example, creating allergen-free formulations, adjusting doses not available commercially, or supplying a drug when the commercially manufactured version is unavailable.

During the FDA drug shortage of semaglutide that began in 2022 and continued through much of 2024 and into 2025, compounding pharmacies were legally permitted to produce compounded semaglutide for patients who could not obtain the brand-name product. This opened a large market for telehealth providers to offer compounded semaglutide at prices far below brand-name equivalents.

The compounded version uses the same active pharmaceutical ingredient (semaglutide sodium or semaglutide base) but is not the same product as Wegovy or Ozempic. It has not undergone FDA review for efficacy, safety, or manufacturing quality at the product level.

The Regulatory Landscape in 2026

The legal status of compounded GLP-1 medications has shifted. The FDA removed semaglutide from its drug shortage list in early 2025, which triggered a change in the regulatory authority under which compounders could legally produce it. Some compounding pharmacies have continued to produce semaglutide under different legal theories; others have shifted to tirzepatide, which had its own shortage designation.

What this means for telehealth patients:

• The legal landscape for compounded GLP-1s is genuinely complex and actively evolving
• Reputable telehealth providers and compounding pharmacies track regulatory changes and adjust their practices accordingly
• Providers that are vague or dismissive about regulatory questions are a red flag
• Patients should ask their provider to explain the current legal basis for the compounded medication they are prescribing

This is not an area to take on faith. A legitimate provider will give you a clear, specific answer.

503B vs. 503A: Why the Pharmacy Type Matters

Not all compounding pharmacies are equivalent. The distinction between 503A and 503B facilities matters significantly for GLP-1 medications.

503A Pharmacies

Traditional compounding pharmacies — classified as 503A facilities — prepare medications on a patient-specific basis, typically in response to individual prescriptions. They are regulated primarily by state pharmacy boards. FDA oversight is limited, and manufacturing standards, while still required, are less stringent than for pharmaceutical manufacturers.

503B Outsourcing Facilities

503B facilities (also called outsourcing facilities) operate under a different regulatory category established by the Drug Quality and Security Act of 2013. They are subject to:

• Current Good Manufacturing Practice (CGMP) standards — the same requirements applied to FDA-approved drug manufacturers
• Regular FDA facility inspections
• Mandatory batch testing for potency, sterility, and stability
• Public disclosure of inspection findings

The practical difference is substantial. A 503B facility is much more likely to produce a consistent, properly potentiated product than a 503A pharmacy. For GLP-1 medications administered by injection, where sterility is a safety concern, the manufacturing standards at a 503B facility provide meaningful risk reduction.

Ask any GLP-1 telehealth provider: Which specific pharmacy do you use? Is it 503A or 503B? What batch testing is performed? Can I see the pharmacy's most recent certificate of analysis?

A provider that cannot or will not answer these questions clearly should not be trusted with your prescription.

Safety Considerations for Compounded GLP-1s

The FDA has issued warnings about compounded semaglutide, citing concerns including:

• Incorrect dosing — Some compounded products have been found to contain incorrect amounts of active ingredient, either more or less than labeled
• Sterility issues — Injectables carry inherent contamination risk if not manufactured under rigorous conditions
• Unauthorized additives — Some compounders have added unapproved ingredients (such as B12 or NAD+) to their formulations without clinical evidence supporting the combination
• Counterfeit products — A market for fraudulently labeled or entirely fraudulent "semaglutide" has emerged outside legitimate compounding channels

These risks are real but manageable when working with a legitimate telehealth provider that sources from a reputable 503B pharmacy. The risk is much higher for products purchased directly online from non-medical websites or overseas sources without a prescription.

When Compounded GLP-1 Makes Sense

Despite the caveats, compounded GLP-1 medications can be a reasonable choice for many patients in specific circumstances:

• Insurance does not cover brand-name GLP-1s for weight management — the most common scenario — and the patient cannot afford $1,000+ per month for brand-name options
• The patient is working with a reputable telehealth provider that uses a 503B-registered pharmacy with transparent quality testing
• The regulatory environment permits compounding of the specific medication at the time of treatment
• The patient is aware of the differences between compounded and brand-name products and has made an informed choice

Compounded GLP-1 therapy is not inherently dangerous. It carries additional uncertainty compared to FDA-approved brand-name products, but for many patients, that tradeoff is acceptable given the dramatic cost difference.

When Brand-Name Is Worth the Premium

Brand-name GLP-1 medications are the stronger choice when:

• Insurance covers the medication — if your plan covers Wegovy or Zepbound, brand-name becomes highly cost-competitive
• A manufacturer savings card applies — eligible commercially insured patients may pay as little as $25 to $99 per month for brand-name products through savings programs
• You have a contraindication history that warrants extra certainty about dosing precision
• You have had a poor experience with compounded products, such as injection site reactions or inconsistent response

How to Vet a Telehealth Provider's Prescribing Approach

Whether you ultimately choose compounded or brand-name, the quality of your telehealth provider's prescribing practice matters more than any other factor. Here is a practical checklist:

1. Ask specifically about their pharmacy. What facility do they use? Is it 503A or 503B? Can they provide the pharmacy name and registration information?
2. Ask about batch testing. Does the pharmacy perform independent third-party testing? How do you obtain the certificate of analysis for your batch?
3. Ask about regulatory compliance. How does the provider ensure the compounded product is being legally prepared? Have they reviewed the FDA's guidance on shortage-based compounding?
4. Check the provider's prescribers. Are they licensed physicians or NPs with verifiable credentials? Are they familiar with obesity medicine?
5. Look for follow-up protocols. A responsible provider monitors patients through titration, not just at initial prescription.

You can compare vetted GLP-1 telehealth providers — including information on their prescribing approach — on VirtualCareFinder's GLP-1 directory.

Making the Decision

The compounded vs. brand-name question ultimately comes down to cost, insurance coverage, and how much certainty you want about the medication you are using.

For most cash-pay patients without insurance coverage for GLP-1s, a well-sourced compounded semaglutide from a 503B pharmacy through a reputable telehealth provider like Ro Body Program offers a reasonable clinical tradeoff. For patients with insurance or access to manufacturer savings programs, brand-name products offer more quality assurance and may cost little more in practice.

Whatever you choose, start with the provider — their medical standards, their pharmacy sourcing, and their follow-up care will shape your experience more than the medication label.

Browse GLP-1 telehealth providers on VirtualCareFinder to compare options and find a program that aligns with your priorities and budget.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide contains the same active ingredient as Ozempic and Wegovy, but it is not the same product. Brand-name GLP-1s go through FDA approval and have standardized manufacturing. Compounded versions are produced by compounding pharmacies, which are not subject to the same FDA review process, though licensed pharmacies are regulated by state boards and, in the case of 503B facilities, by the FDA.

Is compounded semaglutide safe?

Compounded semaglutide from a reputable, licensed pharmacy can be safe, but the FDA has raised concerns about quality control at some compounding facilities. The risk varies significantly by pharmacy. Patients should ask their telehealth provider whether their compounding pharmacy is 503B-registered, what batch testing is performed, and whether the pharmacy has had any FDA warning letters.

Why is compounded semaglutide so much cheaper than brand-name GLP-1s?

Brand-name GLP-1s reflect the cost of clinical trials, FDA approval, manufacturing at scale, and patent protection. Compounding pharmacies avoid most of these costs by producing smaller batches without going through FDA approval. The savings are passed to patients, which is why compounded semaglutide can cost 70 to 80 percent less than Wegovy or Ozempic without insurance.

When can telehealth providers legally prescribe compounded GLP-1 medications?

Compounding pharmacies were permitted to produce semaglutide during the FDA drug shortage period that began in 2022. As the FDA removed semaglutide from the shortage list in 2025, the legal authority to compound it has changed. The situation for tirzepatide continues to evolve. Legitimate telehealth providers stay current on compounding regulations and prescribe within applicable legal frameworks.

What is a 503B compounding pharmacy and why does it matter?

503B pharmacies, also known as outsourcing facilities, are held to Current Good Manufacturing Practice (CGMP) standards — the same manufacturing standards that apply to pharmaceutical companies. They undergo regular FDA inspections and are required to conduct batch testing. 503A pharmacies are smaller, patient-specific compounders regulated primarily by state boards with less federal oversight. For GLP-1 medications, sourcing from a 503B pharmacy provides substantially more quality assurance.